HIMS, Hers Stock

HIMS Earnings Preview: Will The Stock Rebound After 25% Drop?
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25% on Friday, Feb 21, after the U.S. FDA announced semaglutide is no longer in shortage.
Here's Why Hims & Hers Health, Inc. (HIMS) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Hims & Hers Stock Dropped Today
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) rating on Hims & Hers stock. Investors are taking the hint, and doing just that.
Why Is HIMS Stock Down So Much? Should You Buy?
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which previously allowed Hims & Hers to sell compounded alternatives. Compounded versions were permitted during the shortage but are now restricted unless they meet specific exceptions.
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic supply chain and meet rising demand for personalized medications. The deal’s terms were not disclosed.
Hims & Hers Health Stock: A Millionaire-Maker in the Making?
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers is a healthcare giant with millions of users. If that happens, I don't doubt the stock could change lives, even after its epic run thus far.
HIMS Stock To Rise >100% Again?
We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely
Hosted on MSN23m
What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle
Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers’ 458% Rally Tested as FDA Undercuts Obesity Sales
The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...
Hosted on MSN9h
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide Update
Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
HIMS Stock Rockets on At-Home Blood Test Plans
Hims & Hers Health (HIMS) stock rocketed higher today after the telehealth platform operator announced plans to introduce ...
Analysts explain why Hims & Hers stock is crashing today
On Friday, shares of Hims&Hers Health Inc (NYSE:HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE:NVO)'s weight loss and diabetes drugs was ending.